GlassScriptPhysician profile
Leslie Mead
NPI 1194272435
$2,388.80
in general payments reported to CMS, 2019-2025
28 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $975 · 2022: $473 · 2023: $331 · 2024: $273 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.73 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.04 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Nestle Healthcare Nutrition INC. | $226.18 | 2021 | |
| Celgene Corporation | $216.06 | 2021-2023 | Zeposia |
| Vivus LLC | $126.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.00 | 2021-2025 | Eohilia, Entyvio |
| Regeneron Healthcare Solutions, INC. | $94.13 | 2022-2024 | Dupixent |
| Madrigal Pharmaceuticals | $88.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Teva Pharmaceuticals USA, INC. | $53.67 | 2023-2024 | Austedo Xr |
| Evoke Pharma, INC. | $47.06 | 2021-2025 | Gimoti |
| Aimmune Therapeutics, INC. | $43.57 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $43.48 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $40.11 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $31.56 | 2023 | |
| Phathom Pharmaceuticals, INC. | $30.66 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $30.43 | 2024 | Spinraza |
| Csl Behring | $27.50 | 2024 | Hizentra |
| Harmony Biosciences LLC | $26.22 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $26.13 | 2025 | Iqirvo |
| Ethicon US, LLC | $23.80 | 2025 | Echelon Circular |
| Merck Sharp & Dohme LLC | $23.25 | 2021 | |
| Gilead Sciences, INC. | $21.74 | 2023 | |
| Exact Sciences Corporation | $20.75 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $20.71 | 2023 | Sunosi |
| Janssen Biotech, INC. | $18.99 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.42 | 2023 | Lioresal (Baclofen) |
| Neurocrine Biosciences, INC. | $14.96 | 2024 | Ingrezza |
| Davol INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Mead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.